SAN DIEGO, Sept. 14 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the appointment of Dr. Declan Doogan as Executive Vice President and Chief Medical Officer.
"We are very excited to have Dr. Doogan join the Prometheus team," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "Declan's extensive worldwide experience in translational medicine and clinical development in key strategic areas will play an important role as we continue to execute our growth strategy for therapeutics and diagnostics, and build on our success."
Dr. Doogan joins Prometheus with over 30 years of drug development experience primarily with Pfizer Inc. Most recently Dr. Doogan was Interim Chief Executive Officer of Amarin Corporation and Head of Research and Development. Prior to Amarin, Dr. Doogan was Senior Vice President and Head of Worldwide Development at Pfizer Global Research. Dr. Doogan holds Visiting Professorships at Harvard, Glasgow and Kitasato Universities. In addition, Dr. Doogan holds a number of non-executive directorships in the US and the UK. Dr. Doogan received his medical degree from Glasgow University in the UK. He is a Fellow of the Royal College of Physicians of Glasgow and the Faculty of Pharmaceutical Medicine in the UK.
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.
SOURCE Prometheus Laboratories Inc.